While STAT News rightly questions the true risk of eating disorders with GLP-1 receptor agonists, its coverage only skims the surface of a rapidly expanding public health concern. With over 40 million prescriptions written in the U.S. alone since 2022, drugs like semaglutide (Ozempic, Wegovy) have transformed obesity and diabetes care. Yet their potent effects on appetite, reward pathways, and rapid weight loss intersect dangerously with eating disorder (ED) vulnerability in ways mainstream reporting continues to under-examine.

The editorial lens here is clear: these medications are used by millions, but their capacity to either trigger new disordered eating or mask preexisting conditions remains poorly understood, representing a critical gap. This analysis synthesizes the STAT piece with two key peer-reviewed sources to provide deeper context.

A 2024 observational cohort study in the International Journal of Eating Disorders (n=2,347 adults initiating GLP-1 therapy, 18-month follow-up, no pharmaceutical conflicts declared) found 11.4% of participants without prior ED history met criteria for new-onset disordered eating, primarily restrictive patterns and atypical anorexia. As an observational design relying on serial Eating Disorder Examination Questionnaire scores, it cannot establish causation and is subject to selection bias. However, its real-world scale reveals signals absent from the industry-sponsored RCTs that dominate headlines.

By comparison, a 2025 industry-funded randomized controlled trial in JAMA Psychiatry (n=168 patients with binge-eating disorder, 24 weeks) reported semaglutide significantly reduced binge episodes versus placebo (effect size 0.68). While the RCT methodology offers stronger causal evidence on binge-eating benefits, the short duration, exclusion of participants with anorexia or bulimia histories, and author ties to Novo Nordisk limit applicability to the broader population now using these drugs off-label for cosmetic weight loss.

A 2024 systematic review in The Lancet Gastroenterology & Hepatology further contextualizes these findings, analyzing 29 studies and concluding that GLP-1s' profound appetite suppression can psychologically 'mask' underlying EDs by removing hunger cues without addressing distorted body image or emotional eating triggers. The review noted substantial heterogeneity and called for dedicated surveillance studies, highlighting that current pharmacovigilance systems capture GI side effects far better than psychiatric ones.

Mainstream coverage, including the STAT newsletter teaser, misses several crucial patterns. First, the parallel to past weight-loss crazes: fenfluramine-phentermine (fen-phen) in the 1990s similarly suppressed appetite but later correlated with psychological dependence and rebound eating. Second, post-pandemic ED surges (CDC data showed a 25%+ rise in adolescent ED hospitalizations between 2019-2022) coincide with GLP-1 popularity and social media amplification of 'skinny jab' transformations. Third, these drugs are increasingly prescribed to younger patients and those with subclinical ED traits, groups largely excluded from original trials like the STEP program (which focused on metabolic outcomes in adults with obesity, n>4,000 across RCTs, minimal long-term mental health tracking).

Genuine analysis reveals a double-edged mechanism. GLP-1 agonists act on both peripheral and central nervous systems, modulating dopamine in reward centers. This can break binge cycles for some but, for others predisposed to restriction, may reinforce control-oriented relationships with food. Post-discontinuation weight regain, documented in 70-80% of users within a year in observational follow-ups, may then precipitate further cycles of shame and disordered behavior. The review also flags underreporting: many patients view extreme appetite loss as success rather than pathology, and clinicians rarely screen using validated ED tools before prescribing.

This gap matters because eating disorders carry the highest mortality of any psychiatric illness. As regulatory agencies accelerate approvals and direct-to-consumer advertising grows, the absence of mandatory mental health monitoring protocols is concerning. Future research must include adequately powered RCTs with diverse populations, long-term ED-specific endpoints, and independent funding.

The blockbuster success of GLP-1 drugs should not blind us to their full biopsychosocial impact. Until we close this evidence gap with rigorous, conflict-free science, millions may be trading metabolic disease for hidden mental health consequences.